Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on viral hepatitis in 2004.

Scott K Fung1, Anna S F Lok

  • 1Division of Gastroenterology, University of Michigan, Ann Arbor, 48109, USA.

Current Opinion in Gastroenterology
|April 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No impact of low-dose nivolumab addition to JNJ-73763989 on HBsAg declines in chronic hepatitis B: the OCTOPUS-1 study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss.

Hepatology communications·2026
Same author

Update on combination therapies against HBV in clinical investigations.

Antiviral research·2025
Same author

The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada.

Canadian liver journal·2025
Same author

Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Recurrent Erythropoietic Protoporphyria Post Liver Transplant.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025

Recent advances in viral hepatitis treatment show new options for hepatitis B and C. Newer therapies like pegylated interferon and adefovir offer improved outcomes for chronic hepatitis B and C virus infections.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Viral hepatitis remains a significant global health concern.
  • Effective management strategies are crucial for preventing long-term complications.

Purpose of the Study:

  • To summarize recent advancements in viral hepatitis research from December 2003 to November 2004.
  • To highlight novel and clinically relevant findings in hepatitis B and C virus infections.

Main Methods:

  • Literature review of PubMed-indexed studies.
  • Selection of articles reporting significant findings in viral hepatitis.

Main Results:

  • Lamivudine reduces long-term complications in hepatitis B virus (HBV)-induced cirrhosis.

Related Experiment Videos

  • Adefovir suppresses lamivudine-resistant HBV; pegylated interferon shows efficacy in chronic hepatitis B.
  • Optimal treatment for hepatitis C virus (HCV) depends on genotype, with pegylated interferon plus ribavirin effective in coinfected patients.

    • Conclusions:

    • Management of chronic viral hepatitis is rapidly evolving with new treatment options.
    • Pegylated interferon, tenofovir, and combination regimens are effective for hepatitis B.
    • Significant progress in treating difficult-to-treat hepatitis C patients, including coinfected individuals.